company background image
4128 logo

Microbio TPEX:4128 Stock Report

Last Price

NT$44.80

Market Cap

NT$25.1b

7D

3.2%

1Y

-26.7%

Updated

27 Mar, 2024

Data

Company Financials

4128 Stock Overview

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan.

4128 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis


Microbio Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Microbio
Historical stock prices
Current Share PriceNT$44.80
52 Week HighNT$63.87
52 Week LowNT$42.80
Beta1.38
1 Month Change-4.88%
3 Month Change-10.93%
1 Year Change-26.72%
3 Year Change-13.85%
5 Year Change292.69%
Change since IPO346.16%

Recent News & Updates

Recent updates

Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Jan 04
Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Shareholder Returns

4128TW Personal ProductsTW Market
7D3.2%1.0%1.1%
1Y-26.7%-8.6%26.7%

Return vs Industry: 4128 underperformed the TW Personal Products industry which returned -8.6% over the past year.

Return vs Market: 4128 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 4128's price volatile compared to industry and market?
4128 volatility
4128 Average Weekly Movement4.5%
Personal Products Industry Average Movement3.4%
Market Average Movement4.2%
10% most volatile stocks in TW Market7.9%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 4128 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4128's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aHsien-Shou Kuohttps://www.microbio.com.tw

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu.

Microbio Co., Ltd. Fundamentals Summary

How do Microbio's earnings and revenue compare to its market cap?
4128 fundamental statistics
Market capNT$25.10b
Earnings (TTM)-NT$1.18b
Revenue (TTM)NT$1.59b

15.8x

P/S Ratio

-21.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4128 income statement (TTM)
RevenueNT$1.59b
Cost of RevenueNT$987.51m
Gross ProfitNT$603.88m
Other ExpensesNT$1.78b
Earnings-NT$1.18b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.11
Gross Margin37.95%
Net Profit Margin-74.14%
Debt/Equity Ratio0%

How did 4128 perform over the long term?

See historical performance and comparison

Dividends

0.08%

Current Dividend Yield

-1%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.